What do systematic reviews say?

Immunisation outreach vs usual care

The review found no eligible studies for this question.

• Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Integration of immunisation with other health services vs usual care

The review found no eligible studies for this question.

• Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pharmaceutical care vs usual care

• Interventions to improve the appropriate use of polypharmacy for older people 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 691 participants
  Very low

Pharmaceutical care vs usual care

It is very uncertain whether pharmaceutical care changes the proportion of patients with one or more potential prescribing… compared with usual care (very low certainty).

• Interventions to improve the appropriate use of polypharmacy for older people 2023 · Cochrane Headline outcomes only
  RR 0.5 [0.27, 0.91]
  7 studies · 2765 participants
  Very low

Face‐down positioning vs no face‐down positioning or posturing after macular hole surgery

• Face‐down positioning or posturing after macular hole surgery 2023 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 699 participants
  Moderate

Summary of findings table ‐ Psychosocial interventions intended primarily to reduce antipsychotic use vs (Optimised) usual care

• Psychosocial interventions for reducing antipsychotic medication in care home residents 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  Low

Summary of findings table ‐ Psychosocial interventions intended primarily to reduce antipsychotic use vs (Optimised) usual care

• Psychosocial interventions for reducing antipsychotic medication in care home residents 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Low

Anti‐vascular endothelial growth factor (anti‐VEGF) with or without pan‐retinal photocoagulation (PRP) vs PRP alone

Anti‐vascular endothelial growth factor (anti‐VEGF) with or without… probably leads to lower presence of vitreous haemorrhaged compared with PRP alone (moderate certainty).

• Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy 2023 · Cochrane Headline outcomes only
  RR 0.72 [0.57, 0.9]
  6 studies · 1008 participants
  Moderate

CBT vs control

• Psychological interventions for women with non‐metastatic breast cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  27 studies · 3321 participants
  Low

Antibiotics vs no antibiotics

Summary of findings table ‐ Antibiotics showed no clear difference in clinical pregnancy rate (CPR) compared with control (no antibiotics) (low certainty).

• Antibiotics prior to or at the time of embryo transfer in ART 2023 · Cochrane Headline outcomes only
  OR 1.01 [0.67, 1.55]
  2 studies · 377 participants
  Low

Immunomodulatory interventions vs placebo

Immunomodulatory interventions may leads to higher adverse events of glucocorticoids and immunosuppressive drugs compared with placebo (low certainty).

• Immunomodulatory interventions for focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 1.16
  1 study · 66 participants
  Low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 204 participants
  Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  Moderate

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 944 participants
  Low